Bitte beachten Sie: Im Zeitraum vom 21.12.2024 bis zum 07.01.2025 werden auf hohPublica keine Anfragen oder Publikationen durch das KIM bearbeitet. Please note: KIM will not process any requests or publications on hohPublica between December 21, 2024 and January 7, 2025.
 

A new version of this entry is available:

Loading...
Thumbnail Image

Abstract (English)

Aggressive tumors evade cytotoxic T lymphocytes by suppressing MHC class-I (MHC-I) expression that also compromises tumor responsiveness to immunotherapy. MHC-I defects strongly correlate to defective expression of NLRC5, the transcriptional activator of MHC-I and antigen processing genes. In poorly immunogenic B16 melanoma cells, restoring NLRC5 expression induces MHC-I and elicits antitumor immunity, raising the possibility of using NLRC5 for tumor immunotherapy. As the clinical application of NLRC5 is constrained by its large size, we examined whether a smaller NLRC5-CIITA fusion protein, dubbed NLRC5-superactivator (NLRC5-SA) as it retains the ability to induce MHC-I, could be used for tumor growth control. We show that stable NLRC5-SA expression in mouse and human cancer cells upregulates MHC-I expression. B16 melanoma and EL4 lymphoma tumors expressing NLRC5-SA are controlled as efficiently as those expressing full-length NLRC5 (NLRC5-FL). Comparison of MHC-I-associated peptides (MAPs) eluted from EL4 cells expressing NLRC5-FL or NLRC5-SA and analyzed by mass spectrometry revealed that both NLRC5 constructs expanded the MAP repertoire, which showed considerable overlap but also included a substantial proportion of distinct peptides. Thus, we propose that NLRC5-SA, with its ability to increase tumor immunogenicity and promote tumor growth control, could overcome the limitations of NLRC5-FL for translational immunotherapy applications.

File is subject to an embargo until

This is a correction to:

A correction to this entry is available:

This is a new version of:

Notes

Publication license

Publication series

Published in

International journal of molecular sciences, 24 (2023), 8, 7206. https://doi.org/10.3390/ijms24087206. ISSN: 1422-0067
Faculty
Institute

Examination date

Supervisor

Edition / version

Citation

DOI

ISSN

ISBN

Language
English

Publisher

Publisher place

Classification (DDC)
610 Medicine and health

Original object

Standardized keywords (GND)

Sustainable Development Goals

BibTeX

@article{Santharam2023, url = {https://hohpublica.uni-hohenheim.de/handle/123456789/16332}, doi = {10.3390/ijms24087206}, author = {Santharam, Madanraj Appiya and Shukla, Akhil and Levesque, Dominique et al.}, title = {NLRC5-CIITA fusion protein as an effective inducer of MHC-I expression and antitumor immunity}, journal = {International journal of molecular sciences}, year = {2023}, volume = {24}, number = {8}, }
Share this publication